Company intelligence / Profile preview

Nextrast Inc

Hillsborough, California, United Statesnextrast.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Nextrast is developing novel contrast agents to enhance medical imaging, particularly dual-energy computed tomography. Their lead agent, CZ10, is in a Phase 1 clinical trial evaluating safety and initial effectiveness in healthy volunteers. Preclinical studies have shown high safety and efficacy as an intravenous CT contrast agent. Another pipeline asset, NX-9, targets gastrointestinal neoplasms but has not yet reached clinical approval.

Therapeutic areas: Oncology
Modalities: Contrast agents (specifically silicon-based, orally administered and intravenous contrast media for imaging)
Industry: Biotech

Drug pipeline

3 assets

NX9 Oral Contrast Agent

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Nextrast Inc.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nextrast Inc.

Explore the full profile